School of Medicine
Showing 861-870 of 952 Results
-
Junjie Lu
Ph.D. Student in Epidemiology and Clinical Research, admitted Autumn 2023
BioJunjie's research is centered on the social determinants of minority health, epidemiological methods, and clinical effectiveness. He is deeply committed to understanding the health disparities faced by minority populations. His clinical background helps bridge the gap between research and practical application, aiming to improve healthcare outcomes in real-world settings.
Junjie Lu earned a Master of Public Health degree from the Harvard T.H. Chan School of Public Health, where he concentrated on Health and Social Behavior. He also holds an MBBS and an MS from Shanghai University of Traditional Chinese Medicine. Junjie gained practical experience as an intern doctor at a university hospital for two years, during which he led a pilot randomized controlled trial on the effects of acupuncture on depressive symptoms. -
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.
As a physician, Sydney’s group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of ‘wet-lab’ and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.
Sydney’s research is/has been supposed by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute.
